Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
Phase 1 Completed
13 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Phase 1 Recruiting
54 enrolled
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Phase 1/2 Completed
351 enrolled 56 charts
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Phase 2 Completed
53 enrolled 14 charts
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Phase 1 Completed
15 enrolled
ARIA
Phase 1/2 Withdrawn
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
Phase 2 Terminated
9 enrolled 10 charts
PKB115125
Phase 1 Completed
90 enrolled
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Phase 2 Completed
101 enrolled 20 charts
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Phase 4 Unknown
130 enrolled
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
Phase 3 Terminated
90 enrolled 10 charts
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
Phase 1/2 Completed
58 enrolled 11 charts